The Ante-Amyloid Treatment of Alzheimer’s disease (A3) Trial and Alzheimer Plasma Extension (APEX) Study

The goal of the AHEAD 3-45 Study is to determine whether treatment with BAN2401 is superior to placebo on change from baseline of the Preclinical Alzheimer’s disease (AD) Cognitive Composite 5 (PACC5) at 216 weeks of treatment, and determine whether treatment with BAN2401 is superior to placebo in reducing brain amyloid accumulation as measured by amyloid PET at 216 weeks of treatment.